Product Description
Lactobacillus salivarius CECT5713 isolated from breast milk
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biosearch
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Infertility|Abortion, Spontaneous
Phase 1: Vision, Low
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06290518 |
PROBIFERT P051 | N/A |
Completed |
Infertility |
2023-05-03 |
2024-03-05 |
Primary Endpoints|Treatments |
|
NCT05896657 |
PROBIFERT P051 | N/A |
Active, not recruiting |
Abortion, Spontaneous|Infertility |
2023-05-03 |
2023-06-10 |
Primary Endpoints |
|
NCT00724204 |
P010 | P1 |
Completed |
Vision, Low |
2007-09-01 |
2019-03-18 |
Treatments |
|
NCT04446572 |
PREPROBIFERT01 | P2 |
Completed |
Infertility|Abortion, Spontaneous |
2019-11-29 |
2020-06-30 |
Primary Endpoints|Treatments |